7/11/2013

Loxo Oncology and Array BioPharma agreed to co-develop the latter's preclinical drug candidate that targets an oncogenic activating mutation. The partners also agreed to collaborate in the discovery and development of small-molecule compounds against oncology targets chosen by Loxo. The deal entitles Array to as much $434 million in milestone fees plus sales royalties.

Related Summaries